| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 3.6K | 0.7% | 4.6% |
| Total Income | 3.6K | 0.7% | 4.6% |
| Expenditure | 3.1K | 3.5% | 5.6% |
| PBT | 358.71 | 17.5% | 16.2% |
| Net Profit | 222.93 | 16.0% | 48.3% |
| OPM | 13.95% | 2.34pp | 0.84pp |
| NPM | 6.23% | 1.24pp | 1.84pp |
| EPS | 3.49 | 14.9% | 67.0% |
DaVita Inc. Reports Q3 2026 Financial and Operating Results
30 Oct 2026 · 2h ago
Summary
DaVita Inc. announced its financial and operating results for the quarter ended September 30, 2026. Consolidated revenues reached $3.578 billion, with operating income at $499 million and adjusted operating income at $561 million. Diluted earnings per share were $3.40, and adjusted diluted earnings per share were $3.82. The company generated $519 million in operating cash flow and $276 million in free cash flow. Management provided updated 2026 guidance for adjusted operating income, adjusted diluted net income per share, and free cash flow.
Key Highlights
- 1
Consolidated revenues for the quarter ended September 30, 2026, were $3.578 billion.
- 2
Operating income for the quarter was $499 million, with an adjusted operating income of $561 million.
- 3
Diluted earnings per share for the quarter stood at $3.40, and adjusted diluted earnings per share was $3.82.
- 4
Operating cash flow for the quarter was $519 million, and free cash flow was $276 million.
- 5
Total U.S. dialysis treatments for the third quarter of 2026 were 7,329,644, an increase of 0.1% per day compared to the second quarter of 2026.
- 6
The company repurchased 0.6 million shares of common stock for $111 million during the three months ended September 30, 2026.
- 7
As of September 30, 2026, DaVita provided dialysis services to approximately 298,100 patients at 3,269 outpatient dialysis centers.
Informational and educational content only. Not investment advice.